For individuals with T2D, findings are more than numeric; a 5-mm Hg reduction in SBP reduces stroke risk by 14%, CV events by 6%, and heart failure by 8%, authors wrote.
The novel triple fixed-dose combination of telmisartan, amlodipine and indapamide, is the first of its kind approved for initial treatment of hypertension.
Adults with both HTN and T2D had more than twice the risk of all-cause mortality and nearly three times the risk of cardiovascular mortality, according to new data.
For every 10% increase in energy from high-quality carbohydrates, the odds of healthy aging rose by 31%, according to an analysis of data from the Nurse's Health Study.